Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Verstappen, Gwenny Mde Wolff, Liseth
Arends, Suzanne
Heiermann, Hella-Marie
van Sleen, Yannick
Visser, Annie
Terpstra, Janneke H
Diavatopoulos, Dimitri A
van der Heiden, Marieke
Vissink, Arjan
van Baarle, Debbie
Kroese, Frans G M
Bootsma, Hendrika
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.Published in
RMD open 2022;8(1):e002265PMID
35414631ae974a485f413a2113503eed53cd6c53
10.1136/rmdopen-2022-002265
Scopus Count
Collections
Related articles
- Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
- Authors: Nam M, Seo JD, Moon HW, Kim H, Hur M, Yun YM
- Issue date: 2021 Dec 22
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
- Authors: Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, Salvador N, Franco MM, de Avila Mendonça RN, Queiroz Oliveira IS, de Freitas Souza BS, Fraga M, Aley P, Bibi S, Cantrell L, Dejnirattisai W, Liu X, Mongkolsapaya J, Supasa P, Screaton GR, Lambe T, Voysey M, Pollard AJ, RHH-001 study team.
- Issue date: 2022 Feb 5
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
- Authors: Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN, COV-BOOST study group.
- Issue date: 2021 Dec 18
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
- Authors: Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert LJ, Tscheak P, Schmidt ML, Riege J, Solarek A, von Kalle C, Dang-Heine C, Gruell H, Kopankiewicz P, Suttorp N, Drosten C, Bias H, Seybold J, EICOV/COVIM Study Group., Klein F, Kurth F, Corman VM, Sander LE
- Issue date: 2021 Nov
- Humoral immune response after different SARS-CoV-2 vaccination regimens.
- Authors: Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A
- Issue date: 2022 Jan 21